Field Trials

RNS Number : 9078E
Plant Health Care PLC
02 October 2008
 



2 October 2008


 

 

Plant Health Care plc

('Plant Health Care' or 'the Company')


IMPRESSIVE YIELD GAINS FROM SOUTH AFRICAN HARPIN TRIALS


Plant Health Care (AIM: PHC.L), a leading provider of natural products to the agriculture and landscape industries, announces that independent trials of a Harpin based treatment, on commercial potato production in South Africa, have resulted in significant yield gains compared to conventional chemical treatments. 


The comparison trials were undertaken in South Africa, by Bayagro, an important distributor to the potato industry, and presented to the Potato Seed Council of South Africa to show the efficacy of 20 combination chemical and natural potato treatments. This trial was conducted to establish a new 'best practice' for potato growing in South Africa. 


The results showed that a Harpin based product, when used in conjunction with a standard treatment, yielded 8.1% more than all other treatments, including the current industry standard. These results have established Harpin as the new standard treatment for potato production in South Africa.


As a result of these successful trials Jason Holohan, Managing Director of UK/Spain, was invited as a guest speaker to address the recent annual South African Seed Potato Growers Forum. This forum represents growers from the potato industry in South Africa which harvests over 60,000 hectares.


John Brady, CEO of Plant Health Care commented, 'South Africa represents a new and exciting market for PHC. As a result of Jason's initiative in this market and the resultant successful trials we have received significant orders for the remainder of the 2008 season as well as for 2009. We now have a strong distributor in this market and look forward to initiating sales into a variety of crops with both Harpin and Myconate.'


- ends -


For Further Information:


John Brady

Evolution Securities Limited

Tavistock Communications

Chief Executive

Tim Worlledge/Tim Redfern

Jeremy Carey/Simon Compton

Tel: 001 603 525 3702

Tel: 020 7071 4300

Tel: 020 7920 3150




This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAKEAESEPFEE
UK 100

Latest directors dealings